Ten-year outcome of Eculizumab in kidney transplant recipients with atypical hemolytic uremic syndrome— a single center experience

Sam Kant 1, Anshul Bhalla 2, Sami Alasfar 1 and Nada Alachkar 1 *

Abstract

Background: Atypical hemolytic uremic syndrome (aHUS) can result in severe kidney dysfunction, secondary to thrombotic microangiopathy. Eculizumab has been used to treat this disorder, and has resulted in favourable outcomes in both, native and transplanted kidneys. There is limited long term follow up data in kidney transplant recipients (KTRs) who received prevention and treatment with Eculizumab. We report our long term follow up data from our center to address safety and efficacy of this therapy in KTRs.

Methods: We performed a retrospective analysis of KTRs between January 2009 and December 2018. Clinical diagnosis of aHUS established with presence of thrombotic microangiopathy, acute kidney injury, absence of alternate identifiable etiology. We reviewed clinical data, including genetic testing for complement factor mutations, post-transplant course, and response to therapy including therapeutic and prophylactic use of eculizumab.

Results: Nineteen patients with aHUS received a total of 36 kidney transplants; 10 of them had 2 or more prior kidney transplants. Median age at time of last transplant was 37 years (range 27–59), 72% were female (n = 14), 78% Caucasian (n = 15), with 61% had live donor transplant (n = 12) as the last transplant. Eculizumab prophylaxis was given to 10/19 (56%) at the time of transplantation, with no aHUS recurrence during the follow up. Median duration of follow up was 46 (range 6–237) months. Mean estimated glomerular filtration rate (eGFR) at the time of last follow up was 59.5 ml/min/m². No infections secondary to encapsulated organisms or other major infectious complications occurred during the follow up.

Conclusions: Eculizumab prophylaxis is safe and effective in KTRs with aHUS. Long term follow up demonstrates that it may be possible to discontinue prophylaxis carefully in selected patients with no evidence of complement mutations.

Keywords: Eculizumab, Atypical hemolytic uremic syndrome, Kidney transplant

© The Author(s). 2020 Open Access This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article’s Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article’s Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit http://creativecommons.org/licenses/by/4.0/. The Creative Commons Public Domain Dedication waiver (http://creativecommons.org/publicdomain/zero/1.0/) applies to the data made available in this article, unless otherwise stated in a credit line to the data.
Background
Atypical hemolytic uremic syndrome (aHUS) is a rare disorder characterized by thrombotic microangiopathy, as a result of abnormal activation of alternate complement pathway [1]. Ensuing endothelial injury can lead to severe kidney dysfunction, with a propensity for progression to end stage renal disease (ESRD) and recurrence of the disease after kidney transplant [2]. Complement inhibition using eculizumab, a humanized C5 monoclonal antibody, has been demonstrated to aid in recovery of kidney function in aHUS in native and transplanted kidneys, along with preventing recurrence [3–10].

Recurrence of aHUS continues to be a major issue in the post-transplant period and even many years post transplant. Recovery of renal function as well as normalization of hematological parameters was lower for aHUS episodes involving transplanted than native kidneys [4, 11]. Risk factors include genetic complement mutations (in particular, complement factor H) and previous history of recurrence in kidney transplant recipients (KTRs) [12]. Other factors like ischemia reperfusion injury, immunosuppressive medications and infections can also trigger aHUS recurrence. Commencement of prophylactic therapy with Eculizumab has been advocated in patients at moderate to high risk of recurrence, however, timing of treatment with relation to transplantation or duration of treatment has not been established [2]. Long term data regarding the safety and the efficacy of eculizumab therapy in this patient population is also sparse.

We aim to report our 10-year experience of management of aHUS in KTRs, utilizing Eculizumab in the prevention and the treatment of the disease recurrence.

Methods
Study population
We included all adult (age ≥ 18 years at time of their last kidney transplant) KTRs with aHUS who were transplanted at Johns Hopkins Hospital from 2009 to 2018. This study was approved by the Johns Hopkins Hospital Institutional Review Board (IRB). Clinical diagnosis of aHUS established with presence of thrombotic microangiopathy, acute kidney injury, absence of alternate identifiable etiology. We reviewed clinical data, including genetic testing for complement factor mutations, post-transplant course, and response to therapy including therapeutic and prophylactic use of eculizumab and long-term allograft outcome.

Induction and maintenance immunosuppression
Standard induction therapy was anti-thymocyte globulin (Thymoglobulin, Genzyme) 1.5 mg/kg/day for 5 days and high-dose steroids. The typical steroid regimen was methylprednisolone 500 mg intraoperative, followed by a 50% taper daily for three days. Recipients were then switched to oral prednisone 30 mg/day by post-operative day five. Recipients felt to be at high-risk (e.g. presence of DSA or repeat mismatches) were also given a single dose of anti-CD20 antibody (Rituximab, 375 mg/m2) at time of transplant. Standard maintenance immunosuppression was tacrolimus (goal serum level of 8 to 12 ng/mL in the peri-operative time period), mycophenolate mofetil (2 g/day), and prednisone (tapered to 5 mg/day by three months post-transplant).

aHUS diagnosis and treatment
The diagnosis of aHUS recurrence or de novo post transplant was confirmed by kidney transplant biopsy confirming thrombotic microangiopathy (TMA). Eculizumab prophylaxis protocol at time of transplant: 1200 mg peri-operative initial dose, subsequently 900 mg weekly for four weeks, then 1200 mg on week 5, to continue 1200 mg every 2 weeks. Treatment of recurrent and de novo aHUS post transplant included plasma exchanges followed by intravenous immunoglobulin (IVlg) 100 mg/kg after each plasma exchange session. Additionally, eculizumab was started at 900 mg weekly for four weekly followed by 1200 mg on week five to continue 1200 mg every two weeks. In those who required plasma exchange, each session was also followed by eculizumab 600 mg. The duration of plasma exchange was dictated by the treatment response relying on the hematological parameter, renal function and in some cases pathology. Patients received between 5 and 10 plasma exchange sessions.

All the patients who received prophylactic or therapeutic eculizumab also received meningococcal vaccine. Those who received eculizumab for five years or more, were vaccinated again with a meningococcal vaccine boost. In addition to the vaccine, we elected to have the all the patients on prophylactic antibiotic with amoxicillin (or equivalent in cases of penicillin allergy).

Outcomes
We studied mortality and death-censored graft loss, which censors recipients who died with a functioning graft. We determined cause of death, or graft loss, through medical chart review. We also characterized long-term graft function through longitudinal serum creatinine measurement. We also assessed the side effects of long-term use of eculizumab.

Statistical analysis
The cumulative incidence of mortality and death-censored graft failure was determined through Kaplan-Meier analysis. Date is presented in years. All analyses were performed using Stata 15.0/IC for Mac (College Station, Texas).
Results
We identified 19 patients with aHUS who received a total of 36 kidney transplants (Table 1). Among the 19 patients, 10 had at least one previous transplant. Median age at time of last transplant was 37 years (range 27–59). In the cohort, 72% were female (n = 14), 78% Caucasian (n = 15), with 61% had live donor transplant (n = 12) as the last transplant. Diagnosis of aHUS was attributed to previous failure of at least one kidney transplant in 68% (n = 13) of patients. The clinical characteristics of the study population at the time of most recent transplant are outlined in Table 1. Median duration of follow up was 46 (range 6–237) months.

Elven patients had genetic complement mutations, 37% (n = 7) were noted to have complement factor H (CFH) mutations, 21% (n = 4) had other complement factor mutations or CFH related gene deletions and 42% (n = 8) had no mutations identified on genetic testing (CFH, CFHR3-CFHR1, MCP and THBD).

Since the FDA approval of eculizumab in the aHUS treatment, all patients with aHUS as the cause of ESRD who underwent kidney transplantation in our center received eculizumab prophylactic therapy. The only exception was one patient with membrane cofactor protein (MCP or CD46) mutation. A total of 56% (10 of 19 patients) at the

| Table 1 Clinical characteristics of patients with and without eculizumab prophylaxis at the time of most recent transplant |
|---------------------------------------------------------------|
| Variable                                              | Eculizumab prophylaxis (10 patients, 10 transplants) | No eculizumab prophylaxis (9 patients, 9 transplants) | p-value |
| Age, median years (range)                          | 34 (27–50)                                          | 38 (11–59)                                          | 0.44    |
| Female, n                                           | 8 (80%)                                             | 7 (78%)                                             | 0.91    |
| History of prior transplant, n                      | 6 (60%)                                             | 4 (44%)                                             | 0.50    |
| Total number of prior transplants, n                | 9                                                   | 7                                                   | –       |
| Caucasian, n                                        | 10 (100%)                                           | 5 (56%)                                             | 0.01    |
| African-American, n                                 | 0 (0%)                                              | 4 (44%)                                             | –       |
| Cause of ESRD, n                                   |                                                     |                                                     |         |
| aHUS                                               | 8 (80%)                                             | 5 (56%)                                             | 0.57    |
| HUS/TTP                                            | 1 (10%)                                             | 2 (22%)                                             |         |
| FSGS                                               | 1 (10%)                                             | 1 (11%)                                             |         |
| HTN                                                | 0 (0%)                                              | 1 (11%)                                             |         |
| Complement mutations, n                            |                                                     |                                                     |         |
| CFH                                                | 4 (40%)                                             | 3 (33%)                                             | 0.25    |
| CFHR3-CFHR1                                        | 2 (20%)                                             | 0 (0%)                                              |         |
| MCP                                                | 0 (0%)                                              | 1 (11%)                                             |         |
| THBD                                               | 0 (0%)                                              | 1 (11%)                                             |         |
| No mutation detected                                | 4 (40%)                                             | 4 (44%)                                             |         |
| Induction therapy, n                               |                                                     |                                                     |         |
| Thymoglobulin                                      | 9 (90%)                                             | 6 (66%)                                             | 0.18    |
| Basiliximab                                        | 1 (10%)                                             | 0 (0%)                                              |         |
| Daclizumab                                         | 0 (0%)                                              | 2 (22%)                                             |         |
| Maintenance therapy, n                             |                                                     |                                                     |         |
| Eculizumab, Tacrolimus, MMF, prednisone             | 10 (100%)                                           | 0 (0%)                                              | –       |
| Tacrolimus, MMF, prednisone                        | 0 (0%)                                              | 7 (78%)                                             |         |
| Cyclosporine, MMF, prednisone                      | 0 (0%)                                              | 1 (11%)                                             |         |
| Rapamycin, MMF, prednisone                         | 0 (0%)                                              | 1 (11%)                                             |         |
| Duration of eculizumab, n                          |                                                     |                                                     |         |
| 6 months                                           | 3 (30%)                                              | –                                                   | –       |
| 6 to 30 months                                     | 1 (10%)                                             | –                                                   | –       |
| Lifelong                                           | 6 (60%)                                             | –                                                   | –       |
| Plasmapheresis, n                                  | 0 (0%)                                              | 5 (56%)                                             | 0.006   |

aHUS atypical haemolytic uremic syndrome, HUS/TTP haemolytic uremic syndrome/thrombotic thrombocytopenia purpura, FSGS focal segmental glomerulosclerosis, HTN hypertension, MMF Mycophenolate mofetil
time of most recent transplant received prophylactic eculizumab. Eculizumab was discontinued in 3 patients at 6 months post-transplant, where no genetic mutation was identified, while the other 7 patients remained on lifelong eculizumab prophylactic therapy due to identified complement mutations. Median follow up in this group was 39.5 (range 4–88) months, with no aHUS recurrence during the follow up. Mean estimated glomerular filtration rate (eGFR) at the time of last follow up was 59.5 ml/min/m² (Table 2). Only, one patient developed ESRD after developing T cell mediated rejection and did not have evidence of TMA on biopsy or other signs of aHUS recurrence. Nine patients did not receive eculizumab prophylaxis in the most recent transplant. The outcomes of the most recent transplant compared to those of the eculizumab group presented in Table 2.

We compared the recurrence of aHUS across all allograft incidents, including prior allografts and the most recent allograft incident in all patients (total of 24 allograft incidents without eculizumab prophylaxis and 10 allograft incidents with eculizumab prophylaxis). Recurrent aHUS occurred in 17 allograft (in 13 patients) out of total of 24 (70%) allograft incidents without eculizumab prophylaxis; no recurrence occurred in the 10 allografts incidents treated with eculizumab prophylaxis ($p < 0.001$). In the non-prophylactic group, only 3 out of these allograft incidents were treated with eculizumab at the time of biopsy proven identification of aHUS recurrence post-transplant. Out of these 3 patients, only one did not respond to therapy, as eculizumab was utilized very late in the course, and progressed to ESRD. The second patient responded very well to eculizumab treatment but allograft failed later due to recurrent kidney allograft insults. The third patient responded very well to eculizumab treatment and allograft function remained excellent. Prior to eculizumab era, 14 incidents were treated with plasmapheresis (no renal recovery in any of these patients).

At the end of the follow up period, only 3 allografts were deemed functional in the non-eculizumab prophylactic group, in contrast, other than one allograft failure in the prophylactic group, all 9 allografts are still functioning, Fig. 1.

Table 2. Outcomes of most recent transplant in patients treated with eculizumab prophylaxis pre-transplant versus patients not treated with eculizumab prophylaxis pre-transplant

| Variable                  | Eculizumab prophylaxis (10 patients) | No eculizumab prophylaxis (9 patients) | $p$-value |
|---------------------------|--------------------------------------|----------------------------------------|-----------|
| Follow-up post-transplant, median years (range) | 3.48 (0.36–7.21) | 3.80 (1.30–14.70) | 0.33 |
| aHUS recurrence            | 0 (0%)                               | 2 (22%)                                | 0.15 |
| Graft outcome              |                                      |                                        |           |
| Median creatinine, mg/dL (range) | 1.3 (0.9–2.0) | 1.1 (0.7 to 2.1) | 0.46 |
| Median eGFR, ml/min/m² (range) | 55 (43–76) | 61 (32–92) | 0.55 |
| Hemodialysis, (n)          | 1 (10%)                              | 4 (44%)                                | 0.09 |
| Death, (n)                 | 0 (0%)                               | 0 (0%)                                 | –         |

*aHUS atypical haemolytic uremic syndrome, eGFR estimated glomerular filtration rate*
In this study, 88 patients (47%) were received eculizumab before and during their most recent transplant (group 1). On the other hand, 100 patients (53%; group 2) were treated with eculizumab post-transplantation for recurrent aHUS. All-cause function within 6 months of transplantation was significantly better in group 1 compared with group 2, and allograft survival was significantly better. One meningococcal infection and 3 deaths (unrelated to eculizumab) were reported [14]. This further substantiates the evidence that eculizumab prophylaxis prevented aHUS recurrence and led to better graft outcomes.

Outcomes in patients treated with plasma exchange (PLEX) alone in the post-transplant period were especially poor, with none of the patients achieving renal recovery. PLEX was not efficacious in a French study of 146 patients with aHUS, with 44% of patients receiving PLEX developed ESRD at the first episode of aHUS [15]. In another study, irrespective of PLEX being used, half of patients with post-transplant thrombotic microangiopathy had allograft failure within a year [2].

More than a third of patients in our cohort had complement factor H (CFH) mutations, accounting for a majority of the identified mutations. Previous studies have shown that CFH is the most prevalent mutation leading to development of aHUS [16–18]. Additionally, studies have revealed that the highest graft failure rates have been in patients with CFH mutations- 71% failure at 1 year [19].

In our study, out of the 10 patients treated with eculizumab prophylactically and continued treatment post-transplantation, therapy was ceased in 3 patients within 6–12 months of engraftment, given no mutation detected. In the subsequent follow up period, none of the patients developed recurrence of disease. In a previous case series, a patient with no complement mutation has cessation of prophylactic eculizumab after 28.7 months, with no recurrence during 9 months of follow up [20]. With the longest demonstrated follow up to our knowledge (median 40 months), our study shows that cessation of prophylaxis may be possible with minimal risk of recurrence, in carefully selected patients with no identified complement mutations.

None of the patients treated with Eculizumab in our study had episodes of meningococcal infection. It is being increasingly recognized that meningococcal infection appears to be an uncommon event in patients treated with Eculizumab, whether it be for aHUS or paroxysmal nocturnal hemoglobinuria [3, 4, 7, 11, 21]. Nevertheless, vigilance for this infection should be maintained since, as demonstrated in previous studies, the risk cannot be deemed non-existent [14, 22].

The limitations of this study include the small sample size, retrospective and observational nature of the study and limited to practice at one center, which might have changed over the long period of the study.

**Conclusions**

In conclusion, this study demonstrates one of the longest follow up of kidney transplant recipients treated with Eculizumab reported till date. This further consolidates the safety and efficacy of prophylactic therapy to prevent aHUS recurrence in this patient population. Additionally, it provides a direction for possible cessation of therapy in carefully selected patients with no evidence of complement mutations.
Abbreviations

aHUS: Atypical hemolytic uremic syndrome; ESRD: End stage renal disease; KTR: Kidney transplant recipient; IRB: Institutional Review Board; TMA: Thrombotic microangiopathy; IVIg: Intravenous immunoglobulin; CFH: Complement factor H; eGFR: Estimated glomerular filtration rate; PLEX: Plasma exchange

Acknowledgements

None.

Authors’ contributions

SK data collection, research design, manuscript writing. AB research design, manuscript writing. SA research design, data collection and analysis, manuscript writing. NA: SA: research design, data collection and analysis, manuscript writing. All authors have read and approved the manuscript.

Funding

None.

Availability of data and materials

All data generated or analysed during this study are included in this published article.

Ethics approval and consent to participate

This is a retrospective chart review study approved by the Johns Hopkins Hospital Institutional Review Board (IRB). Patient consent was waived. All ethics in conducting retrospective chart review research were followed closely.

Consent for publication

Not applicable.

Competing interests

Dr. Nada Alachkar is a Section Editor of BMC Nephrology-Transplantation Section. No other financial and non-financial competing interests for any of the authors.

Author details

1 Department of Medicine, Division of Nephrology, The Johns Hopkins University School of Medicine, 600 N Wolfe St, Carnegie 344B, Baltimore, Maryland 21287, USA. 2 Department of Surgery, Division of Transplant Surgery, James D. Eason Transplant Institute, Methodist University Hospital, University of Tennessee Health Science Center, Memphis, TN, USA.

Received: 24 March 2020 Accepted: 10 May 2020

Published online: 20 May 2020

References

1. Noris M, Remuzzi G. Atypical hemolytic-uremic syndrome. N Engl J Med. 2009;361(17):1676–87. https://doi.org/10.1056/NEJMoa0902814.
2. Quintre C, Mucu D, Moulin B, et al. Complement genes strongly predict recurrence and graft outcome in adult renal transplant recipients with atypical hemolytic and uremic syndrome. Am J Transplant. 2013;13(3):663–75. https://doi.org/10.1111/ajt.12077.
3. Licht C, Greenbaum LA, Muus P, et al. Efficacy and safety of eculizumab in atypical hemolytic uremic syndrome from 2-year extensions of phase 2 studies. Kidney Int. 2015;87(3):1061–73. https://doi.org/10.1038/ki.2014.443.
4. Greenbaum LA, Fila M, Ardissino G, et al. Eculizumab is a safe and effective treatment in pediatric patients with atypical hemolytic uremic syndrome. Kidney Int. 2016;89(3):701–11. https://doi.org/10.1016/j.kint.2015.11.026.
5. Fakhouri F, Firi, MD, PhD, Hourmant M, Campistol JM, MD, et al. Terminal complement inhibitor Eculizumab in adult patients with atypical hemolytic uremic syndrome: a single-arm, open-label trial. Am J Kidney Dis. 2016;68(1):84–93. https://doi.org/10.1053/j.ajkd.2015.12.034.
6. Chattelet V, Frémeaux-Bacchi V, Lobbedez T, Ficheux M, Bihl L. Safety and long-term efficacy of Eculizumab in a renal transplant patient with recurrent atypical hemolytic–uremic syndrome. Am J Transplant. 2009;9(11):2644–5. https://doi.org/10.1111/j.1600-6143.2009.02817.x.
7. Legendre CM, Licht C, Muus P, et al. Terminal complement inhibitor Eculizumab in atypical hemolytic–uremic syndrome. N Engl J Med. 2013;368(23):2169–81. https://doi.org/10.1056/NEJMoa1208981.
8. Alasfar S, Alachkar N. Atypical hemolytic uremic syndrome post-kidney transplantation: two case reports and review of the literature. Front Med (Lausanne). 2014;1:152. https://doi.org/10.3389/fmed.2014.00052.
9. Matar D, Naqvi F, Racusen LC, Carter-Monroe N, Montgomery RA, Alachkar N. Atypical hemolytic uremic syndrome recurrence after kidney transplantation. Transplantation. 2014;98(11):1205–12. https://doi.org/10.1097/TP.0000000000000200.
10. Alachkar N, Bagnasco SM, Montgomery RA. Eculizumab for the treatment of two recurrences of atypical hemolytic uremic syndrome in a kidney allograft. Transpl Int. 2012;25(8):93. https://doi.org/10.1111/j.1432-2277.2012.01497.x.
11. Fakhouri F, Hourmant M, Campistol JM, et al. Terminal complement inhibitor Eculizumab in adult patients with atypical hemolytic uremic syndrome: a single-arm. Open Label Trial Am J Kidney Dis. 2016;68(1):84–93. https://doi.org/10.1053/j.ajkd.2015.12.034.
12. Zuber J, Quintre C, Muus P, et al. Eculizumab for atypical hemolytic uremic syndrome recurrence in renal transplantation. Am J Transplant. 2012;12(12):3337–54. https://doi.org/10.1111/j.1600-6143.2012.04252.x.
13. Manani SM, Virzi GM, Giuliani A, et al. Hemolytic uremic syndrome and kidney transplantation: a case series and review of the literature. NEF. 2017;136(3):245–53. https://doi.org/10.1159/000468528.
14. Siedlecki AM, Isbel N, Vande Walle J, James Eggleston J, Cohen DJ. Eculizumab use for kidney transplantation in patients with a diagnosis of atypical hemolytic uremic syndrome. Kidney Int Rep. 2019;4(3):434–46. https://doi.org/10.1016/j.ekir.2018.11.010.
15. Fremaux-Bacchi V, Fakhouri F, Garner A, et al. Genetics and outcome of atypical hemolytic uremic syndrome: a Nationwide French series comparing children and adults. CJASN. 2013;8(4):554–62. https://doi.org/10.2215/CJN.04760512.
16. Zhang T, Lu J, Liang S, et al. Comprehensive analysis of complement genes in patients with atypical hemolytic uremic syndrome. AJN. 2016;43(3):160–9. https://doi.org/10.1111/1523-1755.19986.
17. Caprioli J, Bettinghio P, Zipfel PF, et al. The molecular basis of familial hemolytic uremic syndrome: mutation analysis of factor H gene reveals a hot spot in short consensus repeat 20. JASN. 2001;12(2):297–307.
18. Warwick P, Goodship TH, Donne RL, et al. Genetic studies into inherited and sporadic hemolytic uremic syndrome. Kidney Int. 1998;53(4):836–44. https://doi.org/10.1046/j.1523-1755.1998.00824.x.
19. Noris M, Caprioli J, Bresin E, et al. Relative role of genetic complement abnormalities in sporadic and familial aHUS and their impact on clinical phenotype. CJASN. 2010;5(10):1844–59. https://doi.org/10.2215/CJN.02210310.
20. Levi C, Frémeaux-Bacchi V, Zuber J, et al. Midterm outcomes of 12 renal transplant recipients treated with Eculizumab to prevent atypical hemolytic syndrome recurrence. Transplantation. 2017;101(12):2924. https://doi.org/10.1097/TP.0000000000001909.
21. Hill A, Kelly RJ, Kulasekararaj AG, et al. Eculizumab in paroxysmal nocturnal Hemoglobinuria (PNH): a report of all 153 patients treated in the UK. Blood. 2012;120(21):3472. https://doi.org/10.1182/blood.V120.21.3472.3472.
22. Legendre CM, Campistol JM, Feldkamp T, et al. Outcomes of patients with atypical haemolytic uraemic syndrome with native and transplanted kidneys treated with eculizumab: a pooled post hoc analysis. Transpl Int. 2017;30(12):1275–83. https://doi.org/10.1111/tit.13022.

Publisher’s Note

Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.